<DOC>
	<DOC>NCT02121509</DOC>
	<brief_summary>The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release.</brief_summary>
	<brief_title>Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criteria: Healthy male or female subjects Exclusion criteria: Any relevant deviation from healthy condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>